UPDATE: Mersana (MRSN) PT Lowered to $26 at Wedbush, Following Earnings

February 26, 2021 2:39 PM EST
Get Alerts MRSN Hot Sheet
Price: $15.81 -1.8%

Rating Summary:
    7 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 14 | New: 42
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - February 26, 2021 2:42 PM EST)

(Updated to add analyst comment)

Wedbush analyst David Nierengarten lowered the price target on Mersana (NASDAQ: MRSN) to $26.00 (from $27.00) while maintaining a Outperform rating.

Analyst says: "Our sum-of-parts PT is based on an 8× multiple to projected ww sales of XMT-1536 in 2026 in NaPi2b-high expressing epithelial ovarian cancer and non-small cell lung cancer (NSCLC) (discounted back by 25% annually in ovarian and 40% in NSCLC) and an 8× multiple to projected ww sales of XMT- 1592 in 2028 in NSCLC (discounted back by 40% annually)."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Earnings